Urologic oncology @Yale_Urology | Hon Assoc Prof @UCLDivofSurgery | Hunterian Prof @RCSnews | Previously @MDAndersonNews @UCLH @uclhrobotics @NorthLonUrol
New Haven, CT
Joined December 2016
- Tweets1.6K
- Following1.1K
- Followers1.3K
- Likes6.4K
Wei Shen Tan retweeted
PROTEUS Substudy: Periop Apa + ADT with RP+PLND vs RP+PLND in HR PCa @urotoday #ESMO26
Periop APA + ADT (+ RP+PLND; n= 102) vs RP+PLND alone (n=306)
🚨EFS: HR 0.38, 95% CI 0.26–0.55
🚨MFS: HR 0.49, 95% CI 0.26–0.90
🚨TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43
🚨All Gr Hot Flush: 64% vs 0.7%
Wei Shen Tan retweeted
In advanced #UrothelialCarcinoma, treatment-emergent skin toxic effects during first-line enfortumab vedotin plus pembrolizumab were associated with longer overall survival. ja.ma/4k88Qvf
ALT A horizontal bar chart showing time since EVP indication in months on the x-axis, accompanied by categorical side columns for skin toxic effects, best response, and vital status. Below is a density plot peaking sharply near zero.
Wei Shen Tan retweeted
We’re hiring. The Mu Lab at Yale is recruiting a Postdoctoral Associate in cancer biology, immuno-oncology, AI, and translational research.
Please share with anyone who may be interested.
postdocs.yale.edu/posts/2025…
#Postdoc #CancerResearch #yale
Wei Shen Tan retweeted
1/ Congratulations to the PACE-A investigators. This is important work, and we need more randomized trials like this to move the field forward.
But before we start dancing on the grave of radical prostatectomy, a few things are worth considering. 🧵
#ASTRO26 Plenary -- PACE-A: 5-yr Outcomes of RP vs SBRT for GG1-2 PCa @nickva1 @urotoday
📍n=123 (60 RP, 63 SBRT), mFU 8 yrs, 10 🇬🇧 centers
📍13 BCF events: HR 0.48, 95% CI 0:16-1.46
📍7 deaths (no PCa): HR 0.55, 95% CI 0.12, 2.46
📍EPIC-26 >=1 urinary pad: 14/29 (48%) RP vs 3/36 (8%) SBRT
📍EPIC-26 bowel bother: 1/28 (4%) RP vs 0 SBRT
Wei Shen Tan retweeted
Ever wonder how heterogeneity defines bladder cancer subtypes?
Ha and Hsieh Lab postdoctoral fellows @pushpa_itagi and Samantha Schuster @fredhutch did, leading to a deep study of bladder cancer clonality, evolution, and heterogeneity published @Nature
nature.com/articles/s41586-0…
Wei Shen Tan retweeted
@DrTanWPis crushing it at the @FocalSociety meeting, both at the new guidelines panel and a phenomenal practical session on optimizing margins in partial prostate gland ablation. Great work with Histology system!
Wei Shen Tan retweeted
Just released in @NatRevUrol : Integrating clinically actionable biomarkers into bladder cancer care : recommendations from the International Bladder Cancer Group @IBCG_BladderCA
During our deliberations, one theme was clear: biomarkers don't improve care simply because they're "novel or new" They improve care when they're validated, reproducible, and actually change clinical decisions 🧵
@pjhensley11 @jteoh_hk @UrogerliMD @shilpaonc @LauraBukavinaMD @mouwlab @AndreaNecchi @niyatilobo @Agarwal_CaB @LiangChengMD @karima_oualla @drtanws @MaxKates @BrigidaMaiorano @h_alahmadie @TomFlaigMD @AmirHorowitz @WesKassouf @djmcconkey @JanetKukreja @LAUrology_NL @carme_mir1 @UroMoschini @BogdanaSchmidt @VigneshPackiam
Wei Shen Tan retweeted
With EV-303/304 & NIAGARA, 'sandwich' regimens in MIBC, @FedGhali & I argue that ctDNA is a marker of molecular residual disease and de-escalation is safe for patients with ctDNA(-) & excellent reponse at cystectomy path.
doi.org/10.1111/bju.70377
With EV-303/304 & NIAGARA, 'sandwich' regimens in MIBC, @FedGhali & I argue that ctDNA is a marker of molecular residual disease and de-escalation is safe for patients with ctDNA(-) & excellent reponse at cystectomy path.
doi.org/10.1111/bju.70377
In your practice, would you feel comfortable using post-RC tumor-informed ctDNA(-) and final RC path results to de-escalate a patient to observation instead of giving adjuvant systemic therapy?
11%All ctDNA(-) patients
63%Only if pT0-1 N0 at RC
5%pT0-4 N0 at RC
21%Never/ Need RCT data
19 votes • Final results Wei Shen Tan retweeted
Honoured to receive the award for Best Presentation & Abstract for Colorectal and Oesophageal sections @BritSocGastro
#colorectalpolyps #Barrettsoesophagus – at Liverpool, England
Wei Shen Tan retweeted
Yale Urology is seeking a PGY-3 resident to join our program starting July 1, 2026. We offer exceptional surgical training, high-volume operative experience, all subspecialties, diverse practice settings, research opportunities, and career mentorship. 🧵1 of 2
Wei Shen Tan retweeted
🩺Outcomes of Intermediate Risk Non–muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials
by Wei Shen Tan...John D. Kelly et al
buff.ly/59z3hSm
📢What does this study add?
This study presents a pooled analysis of individual patient data from four randomized controlled trials involving intermediate-risk (IR) non–muscle-invasive bladder cancer (NMIBC). The findings provide valuable estimates of recurrence and progression rates, which can inform clinical trial design, support accurate sample size calculations, and help optimize surveillance strategies for patients with IR-NMIBC.
🙌We thank the authors for trusting EUO with your work!
@drtanws
@UroDocAsh
@NPortaStat
@AlbertoMartini
@ahmostafid
@EmmaHall71
@Heer_Lab
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
IR NMIBC (Recurrent LG) of UK RCT- HIVEC-II, BOXIT, PHOTO, CALIBER suggest that despite 6 weekly induction chemotherapy nearly 50% develop recurrence at 5 yrs
⭐️Important bench mark to beat for upcoming RCT using surveillance as control
shorturl.at/z8Jja
New paper just out in @EurUrolOncol - outcomes of patients with intermediate-risk NMIBC when treated with contemporary protocols?
We analyzed 578 patients across 4 RCTs. IR NMIBC defined as per @IBCG_BladderCA and 2019 EAU Guidelines - only LG tumors.
Real-world relevant data. Here is what we found. 🧵
Ohttps://euoncology.europeanurology.com/article/S2588-9311%2826%2900127-6/fulltext
⭐️Recurrence rate at 36 mo is simillar to 60 mo (44% vs 46%)
⭐️Noncumulative risk of recurrence after initial TURBT beyond 60 months is low suggesting that reducing the frequency/ terminating cystoscopy could be considered
Wei Shen Tan retweeted
People have been DM and asking me: with an HR of 0.68 for durvalumab + BCG in POTOMAC, why isn’t this for every high-risk NMIBC patient?
Here’s how hazard ratios work – and why they can mislead you if you stop there. 🧵 #ASCO26
@tompowles1 @WesKassouf @shilpaonc @DrFelixGuerrero
The approval answers one question, but leaves another unanswered: which patients truly derive enough benefit to justify escalation beyond optimized BCG?
The FDA approval of durvalumab plus BCG in high-risk NMIBC was driven by a meaningful improvement in disease-free survival (HR 0.68), mainly recurrence free survival. Checkpoint inhibitors are not benign therapies, carrying ~ 15% risk of serious treatment-related adverse events.
At the same time, this trial also demonstrated that patients with BCG-naïve high-risk NMIBC have low rates of progression and bladder cancer mortality, when treated with BCG appropriately.
For many patients, the balance between reducing recurrence and exposing them to potentially significant toxicity is not straightforward.
That raises a practical question: who should actually receive treatment intensification?